溶菌酶在脓毒症中的研究进展  

Research progress of lysozyme in sepsis

作　　者：张雅茹 闫新明[1] ZHANG Yaru;YAN Xinming(Department of Emergency Surgery,Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan,Shanxi 030032,China)

机构地区：[1]山西医科大学第三医院(山西白求恩医院山西医学科学院同济山西医院)急诊外科,山西太原030032

出　　处：《中国临床研究》2024年第11期1774-1777,共4页Chinese Journal of Clinical Research

摘　　要：脓毒症作为临床上较常见的疾病,具有发病率高、病死率高、治疗费用高等特点,严重威胁患者的健康。而溶菌酶是一种糖苷水解酶,是在中性粒细胞和巨噬细胞的颗粒中具有广谱抗菌活性的重要蛋白,它不仅能刺激多形核细胞、白细胞和巨噬细胞的吞噬活性,而且具有较高的特异性和较低的毒性,在对抗细菌入侵的先天免疫反应中发挥着重要作用。目前众多临床研究表明脓毒症与溶菌酶的关系密切,本文就溶菌酶与脓毒症的最新研究进展作一综述。Sepsis is a common disease,with high incidence,high mortality,and high cost,seriously threatening the health of patients.Lysozyme,a kind of glycosidase,is an important protein with broad-spectrum antibacterial activity in the granules of neutrophils and macrophages.It can not only stimulate the phagocytic activity of polymorphonuclear cells,leukocytes,and macrophages,but also has high specificity and low toxicity,playing an important role in the innate immune response against bacterial invasion.Currently,many clinical studies have shown a close relationship between sepsis and lysozyme.This article provides an overview of the latest research progress on lysozyme and sepsis.

关 键 词：脓毒症 溶菌酶 抗菌活性 益生菌 血管舒张 生物标记物 

分 类 号：R631[医药卫生—外科学]